文献速递围术期管理与 ERAS胃肠外科肝胆胰外科

择期大型癌症手术后基于风险分层的方案管理随机对照试验

A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
PubMed 文献 · Ann Surg · 2024-07-24

该随机对照试验纳入1529例择期大型癌症手术成人患者,比较基于风险分层升级的监护与共同管理方案与常规管理。结果显示干预组30天术后死亡或严重并发症率为15.0%,常规组为14.1%(P=0.65),两组在并发症、住院时间、生活质量及生存结局上均无差异。

要点

  • 基于风险分层的方案管理未降低30天术后死亡或严重并发症率。
  • 干预未改善并发症、住院时间、再入院率或生活质量。
  • 中位随访48个月,两组总生存和无病生存相似。

核心结论

  • 与常规管理相比,基于风险分层的方案驱动管理未降低择期大型癌症手术后30天死亡或严重并发症率。
  • 该策略也未改善术后医疗资源利用、健康相关生活质量或癌症结局。

研究设计与样本

  • 随机对照试验,2014年8月至2020年6月纳入1529例择期大型癌症手术成人患者。
  • 干预组738例和对照组732例纳入分析,比较基于风险分层升级的监护与共同管理方案 versus 常规管理。

主要发现

  • 干预组30天死亡或严重并发症率为15.0%(95%CI:12.5%-17.6%),常规组为14.1%(95%CI:11.6%-16.6%),P=0.65。
  • 两组30天并发症率、不良事件率(包括重返手术室)、术后住院时间、出院回家率、30/60/90天健康相关生活质量、再入院率或接受抗肿瘤治疗率均无差异。
  • 中位随访48个月,总生存(P=0.57)和无病生存(P=0.91)相似。

临床怎么用

  • 对于择期大型癌症手术,基于风险分层的方案驱动管理未显示优于常规管理,不应常规推广以降低短期严重并发症。
  • 仍需探索成本效益好且个体化的围术期策略以优化大型癌症手术结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of risk-based, protocol-driven management versus usual management after elective major cancer surgery to reduce 30-day rates of postoperative death or serious complications (DSCs). BACKGROUND: Major cancer surgery is associated with significant perioperative risks, which result in worse long-term outcomes. METHODS: Adults scheduled for elective major cancer surgery were stratified/randomized to risk-based escalating levels of care, monitoring, and comanagement versus usual management. The primary study outcome was a 30-day rate of DSC. Additional outcomes included complications, adverse events, health care utilization, health-related quality of life (HRQOL), and disease-free survival and overall survival. RESULTS: Between August 2014 and June 2020, 1529 patients were enrolled and randomly allocated to the study arms; 738 patients in the intervention arm and 732 patients in the control arm were eligible for analysis. Thirty-day rate of DSC with the intervention was 15.0% (95% CI: 12.5%-17.6%) versus 14.1%, (95% CI: 11.6%-16.6%) with usual management ( P = 0.65). There were no differences in 30-day rates of complications or adverse events (including return to the operating room), postoperative length of stay, rate of discharge to home, or 30, 60, or 90-day HRQOL or rates of hospital readmission or receipt of antineoplastic therapy between the study arms. At a median follow-up of 48 months, overall survival ( P = 0.57) and disease-free survival ( P = 0.91) were similar. CONCLUSIONS: Risk-based, protocol-driven management did not reduce the 30-day rate of DSC after elective major cancer surgery compared with usual management, nor did it improve postoperative health care utilization, HRQOL, or cancer outcomes. Trials are needed to identify cost-effective, tailored perioperative strategies to optimize outcomes after major cancer surgery.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Esnaola NF, Chelluri R, Castellanos J, et al. A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery. Ann Surg. 2024. PMID: 39045699. doi:10.1097/SLA.0000000000006446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。